A randomized, double-blind, parallel-group, 2-treatment multiple dose study to assess the intestinal, metabolic and cardiovascular effects of an 8 weeks treatment with sotagliflozin QD as compared with empagliflozin QD in Type-2-diabetes-mellitus patients with mild to moderate hypertension
Phase of Trial: Phase II
Latest Information Update: 31 Oct 2018
At a glance
- Drugs Sotagliflozin (Primary) ; Empagliflozin
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 27 Aug 2018 Planned End Date changed from 1 Oct 2018 to 7 Aug 2019.
- 27 Aug 2018 Planned primary completion date changed from 1 Oct 2018 to 7 Aug 2019.